In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ethicon Buys Acclarent: Can This Exit Open Up ENT?

Executive Summary

Traditionally, the ENT space has been a bit of a technology backwater in terms of device innovation. Indeed, it has been more than a decade since the last major ENT deal, which made Medtronic the sole major strategic player in the ENT space. That dynamic has now changed with J&J/Ethicon's acquisition of Acclarent. Now the question is whether this deal will help open up the ENT space to more M&A activity?

You may also be interested in...



Companies See Opportunities In Expanding ENT Market

The ear, nose, and throat market now boasts several large device manufacturers that see possibilities in this space for innovative new minimally invasive products. Such competition is the ideal landscape for innovation, as the large companies battle for market share, while start-up firms and VCs see opportunities to take the market in new directions.

Companies See Opportunities In Expanding ENT Market

Competition breeds innovation, and the ear, nose, and throat (ENT) market, once a fairly quiet arena, is now positioned to host some spirited activity that should lead to new technologies. Several large device manufacturers have recently moved into the ENT space, and the sinus treatment segment of the market has become one of the focal points for emerging competitors, as companies work toward less-invasive treatment options.

Entellus: Helping The Interventional Revolution Balloon In Sinus Therapy

The second company in the US looking to replace certain sinus surgeries with interventional procedures, Entellus is looking to further advance this technology by moving treatment from the OR to the doctor's office.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1123310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel